MET and primary cutaneous T-cell non-Hodgkin lymphoma: By Western blot analysis, we observed expression of the MET protein in 10/11 (91%) cTCL cases, increased phosphorylation of MET in 6/11 (55%) cTCLs, and mutations in MET were detected in 92% of cTCL tumors.